Research programme: tumour necrosis factors - Human Genome Sciences
Alternative Names: TNFSF18; Tumour necrosis factor ligand superfamily member 18Latest Information Update: 29 Mar 2011
Price :
$50 *
At a glance
- Originator Human Genome Sciences
- Class Tumour necrosis factors
- Mechanism of Action RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 31 Oct 2005 A preclinical study has been added to the Musculoskeletal Disorders pharmacodynamics section
- 30 Jul 2002 Preclinical trials in Postmenopausal osteoporosis prevention in USA (unspecified route)
- 30 Jul 2002 Preclinical trials in Postmenopausal osteoporosis treatment in USA (unspecified route)